Cancer ResearchResearch PaperPaywall

New Lysosomal Stress Pathway Linking TBK1 and TFEB Could Reshape Cancer and Aging Biology

Scientists uncover a nutrient-independent signaling axis that activates TFEB, a master regulator of cellular cleanup, with direct implications for cancer and longevity.

Friday, October 2, 2026 3 views
Published in Nature
A fluorescence microscopy image showing bright punctate lysosomal structures glowing inside a cultured cell, with a visible nucleus, on a dark background in a research laboratory setting

Summary

Lysosomes are cellular recycling centers, and TFEB helps control genes involved in lysosome formation and autophagy. This study identifies a nutrient-independent pathway that activates TFEB during lysosomal stress. Assembly of the lysosomal proton pump v-ATPase promotes recruitment of TBK1 or ULK1 through the adaptor TAX1BP1. Phosphorylation of FNIP1 at S296 inhibits FLCN, allowing TFEB to enter the nucleus. The pathway selectively affects TFEB regulation while preserving mTORC1 signaling to growth-related substrates such as S6K. Recurrent ATP6V1B2 mutations found in follicular lymphoma constitutively activate this pathway; the authors report that this drives TFEB hyperactivation and lymphoma proliferation.

Detailed Summary

The mTORC1 kinase coordinates cellular responses to nutrients and stress. Its regulation of TFEB, a transcription factor controlling lysosomal and autophagy programs, depends on the FLCN–FNIP complex and RagC/D GTPases. This Nature study identifies a nutrient-independent pathway linking lysosomal stress to inhibition of FLCN and activation of TFEB.

In HEK293T cells, the follicular-lymphoma-associated ATP6V1B2 variants Y371C and R400Q strongly impaired mTORC1-mediated phosphorylation of TFEB at S211 and the mTORC1-dependent sites S142 and S138 while preserving S6K phosphorylation. TFEB lost lysosomal association, entered the nucleus and induced target-gene expression. The variants also increased assembly of the V1 and V0 portions of v-ATPase.

Saliphenylhalamide, which promotes V1–V0 association while inhibiting v-ATPase, and the ionophores monensin, nigericin and salinomycin similarly promoted TFEB activation without reducing phosphorylation of S6K and 4E-BP1. TFEB activation also occurred in NPRL3-knockout cells with constitutively active RagA/B. This supports selective regulation of the FLCN–FNIP–RagC/D branch rather than a requirement to inhibit RagA/B.

The experiments connect v-ATPase assembly to CASM, the conjugation of ATG8 proteins to single membranes. Depletion of ATG16L1 rescued TFEB phosphorylation and localization in R400Q-expressing cells, whereas ATG9 depletion did not. Lysosome immunoprecipitation followed by mass spectrometry identified enrichment of ATG8 proteins and TAX1BP1 on R400Q-expressing lysosomes. TAX1BP1 depletion prevented saliphenylhalamide-induced TFEB dephosphorylation and nuclear translocation.

The abstract identifies the downstream mechanism: TAX1BP1 mediates lysosomal recruitment of TBK1 or ULK1, enabling phosphorylation of FNIP1 at S296. This inhibits FLCN and permits TFEB nuclear translocation. The authors report that recurrent ATP6V1B2 mutations constitutively activate this pathway, promoting TFEB hyperactivation and follicular lymphoma proliferation.

The supplied portion supports a mechanistic connection between lysosomal stress signaling and cancer. It does not include the detailed kinase experiments, disease-model growth assays or patient-cohort measurements needed to verify the more specific claims about these results. It also does not establish therapeutic efficacy or effects on aging or lifespan.

Key Findings

  • ATP6V1B2 variants Y371C and R400Q strongly impaired TFEB phosphorylation at S211, S142 and S138 while preserving S6K phosphorylation and promoting TFEB nuclear localization.
  • Saliphenylhalamide and the ionophores monensin, nigericin and salinomycin selectively activated TFEB without reducing S6K or 4E-BP1 phosphorylation.
  • TFEB activation persisted in NPRL3-knockout cells with constitutively active RagA/B, supporting selective regulation of the FLCN–FNIP–RagC/D branch.
  • ATG16L1 depletion rescued TFEB phosphorylation and localization in R400Q-expressing cells, whereas ATG9 depletion did not, implicating CASM rather than conventional autophagy.
  • Lysosomal proteomics identified enrichment of TAX1BP1 and ATG8 proteins in R400Q-expressing lysosomes; TAX1BP1 depletion prevented saliphenylhalamide-induced TFEB activation.
  • The authors identify TAX1BP1-mediated recruitment of TBK1 or ULK1 and FNIP1 S296 phosphorylation as the mechanism inhibiting FLCN and enabling TFEB nuclear translocation.
  • The authors report that recurrent ATP6V1B2 mutations constitutively activate this pathway, promoting TFEB hyperactivation and follicular lymphoma proliferation.

Methodology

The supplied material describes mechanistic experiments in HEK293T cells expressing wild-type or mutant ATP6V1B2, including NPRL3-knockout cells. Methods shown include phosphorylation measurements, immunofluorescence and localization analysis, protein-interaction assays, biochemical fractionation, siRNA depletion, and lysosome immunoprecipitation followed by LC–MS proteomics. Perturbations include saliphenylhalamide and the ionophores monensin, nigericin and salinomycin. The supplied portion does not provide complete methods, replicate counts, statistical procedures or patient-cohort details.

Study Limitations

The supplied source includes the abstract, introduction, early results and part of a figure, rather than the complete paper. The shown experiments include cultured cells expressing mutant ATP6V1B2, but the full range of disease models and patient validation cannot be assessed from this material. Detailed kinase assays, cohort sizes, statistical methods, therapeutic testing and animal experiments are not available here for verification; their absence from the excerpt does not establish their absence from the paper. Funding and competing-interest statements are also not included.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: